Navigation Links
Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
Date:4/23/2012

WASHINGTON, April 23, 2012 /PRNewswire/ --  Covington & Burling represented AstraZeneca in its $1.26 billion acquisition of Ardea Biosciences.  Under the agreement, AstraZeneca will pay $32 per share for all of the outstanding shares of Ardea. 

(Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO )

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. Ardea is a biotechnology company based in San Diego, California, focused on the development of small-molecule therapeutics for the treatment of serious diseases. 

The Covington team was led by Catherine Dargan, with assistance from Stephen Infante and Michael Riella. The team also included John Hurvitz, Emily Leonard, Ashley Nelson, Darien Capron, Brianna Sandoval, Christina Chung, Larry Bartenev and Caitlin Cottingham (life sciences/corporate), Robert Heller and Sarah Burnham (tax), Michael Francese and Katherine Mineka (benefits), Marialuisa Gallozzi and Scott Levitt (insurance), Andrea Reister and Marie Lavalleye (intellectual property), Michael Labson (regulatory), and Deborah Garza, James Dean and Jonathan Herczeg (antitrust). 

Covington & Burling LLP, an international law firm, provides corporate, litigation, and regulatory expertise to enable clients to achieve their goals.  Founded in 1919, the firm has more than 800 lawyers and offices in Beijing, Brussels, London, New York, San Diego, San Francisco, Silicon Valley, and Washington, DC.

Contact

Rebecca Carr


202.662.5110


rcarr@cov.com


'/>"/>
SOURCE Covington & Burling
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. nanoTox COO Greg King Advises Nanotech Companies to View Safety Concerns as an Opportunity to Gain Consumer Trust
2. KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
3. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
4. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
5. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
6. AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer
7. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
8. Rigel Earns Milestone Payments From AstraZeneca
9. TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis
10. AstraZeneca Outlines Principles for Product-Related Online Communications
11. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... -- Aratana Therapeutics, Inc. (NASDAQ: PETX ), ... and commercialization of innovative biopharmaceutical products for companion animals, ... North America 2016. ... the FDA approval of three innovative therapeutics in 2016, ... oral solution) and NOCITA ® (bupivacaine liposome injectable ...
(Date:1/20/2017)... http://www.Financialbuzz.com - According ... causes of death worldwide. There were 8.2 million cancer ... related deaths increased gradually over time, the death rates ... various cancers continues to drive demand of biological therapies ... Market Insights, Inc. cancer biological therapy market size was USD ...
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
Breaking Biology Technology:
(Date:1/12/2017)... research undertaken by Fit Small Business has revealed ... simply asked which office technology had they not used in ... Insights on what will be key features in ... industry leaders including Penelope Trunk , Martin Lindstrom ... Some of these findings included; ...
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
Breaking Biology News(10 mins):